NASDAQ:YMTX Yumanity Therapeutics (YMTX) Stock Price, News & Analysis → top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad) Free YMTX Stock Alerts $0.62 -0.05 (-7.46%) (As of 04/24/2024 ET) Add Compare Share Share Today's Range$0.60▼$0.6750-Day Range$0.34▼$2.8352-Week Range$0.95▼$13.23Volume172,143 shsAverage Volume473,083 shsMarket Capitalization$6.73 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsFinancialsInsider TradesSEC FilingsSocial MediaStock AnalysisChartCompetitorsFinancialsInsider TradesSEC FilingsSocial Media Get Yumanity Therapeutics alerts: Email Address Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… About Yumanity Therapeutics Stock (NASDAQ:YMTX)Yumanity Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of treatments for neurodegenerative diseases caused by protein misfolding. The company focuses on discovering disease-modifying therapies to treat neurodegenerative diseases, including Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, amyotrophic lateral sclerosis, and frontotemporal lobar degeneration. Its lead program is YTX-7739, a novel small molecule that is in Phase I clinical trial for the treatment of Parkinson's disease and related disorders of a-synuclein. The company is also developing YTX-9184, which is in preclinical studies to treat neurological disorders. Yumanity Therapeutics Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. The company was founded in 2014 and is headquartered in Boston, Massachusetts.Read More YMTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart YMTX Stock News HeadlinesApril 24, 2024 | americanbankingnews.comYumanity Therapeutics (NASDAQ:YMTX) Stock Price Up 20.5%March 20, 2024 | seekingalpha.comJSPR Jasper Therapeutics, Inc.April 24, 2024 | GoldenCrest Metals (Ad)Emergency: Biden's $20 Trillion Mistake Could Cost YOU!The stakes have never been higher for your savings. Here's the hard truth: A banking crisis is looming. Your money is in the crosshairs of a $20 trillion commercial loan debt disaster, set to erupt.November 3, 2023 | morningstar.comCara Therapeutics Inc CARAOctober 6, 2023 | thestreet.comYumanity Therapeutics Inc.July 5, 2023 | thestreet.comFormer Onyx CEO Returns to Biotech to Launch Boston Start UpMay 1, 2023 | bizjournals.comKineta raises $6M through registered direct offeringFebruary 22, 2023 | finance.yahoo.comColorectal Cancer Therapeutics Market Size to Surpass US$ 24.58 Billion by 2030 - Growth Plus ReportsApril 24, 2024 | GoldenCrest Metals (Ad)Emergency: Biden's $20 Trillion Mistake Could Cost YOU!The stakes have never been higher for your savings. Here's the hard truth: A banking crisis is looming. Your money is in the crosshairs of a $20 trillion commercial loan debt disaster, set to erupt.December 26, 2022 | msn.comYumanity Therapeutics's Return On Capital Employed InsightsDecember 20, 2022 | bizjournals.comKineta finalizes reverse merger with Yumanity, secures additional fundingDecember 5, 2022 | finance.yahoo.comYumanity Therapeutics Declares Special Dividend In Connection with Proposed Asset Sale to Janssen and Merger with KinetaDecember 5, 2022 | investorplace.comWhy Is Yumanity Therapeutics (YMTX) Stock Up Today?November 14, 2022 | finanznachrichten.deYumanity Therapeutics Inc: Yumanity Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate DevelopmentsNovember 14, 2022 | finance.yahoo.comYumanity Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate DevelopmentsNovember 10, 2022 | finance.yahoo.comYumanity Therapeutics Announces Effectiveness of Registration Statement on Form S-4 In Connection With Proposed Asset Sale to Janssen and Merger with Kineta, Inc.August 29, 2022 | finance.yahoo.comYumanity Therapeutics Announces Filing of Registration Statement on Form S-4 In Connection With Proposed Asset Sale to Janssen and Merger with KinetaAugust 4, 2022 | finance.yahoo.comYumanity Therapeutics Reports Second Quarter 2022 Financial Results and Recent Corporate DevelopmentsJune 8, 2022 | finance.yahoo.comInside Kineta's plans after unveiling reverse merger dealJune 7, 2022 | bizjournals.comSeattle biotech Kineta to go public in merger deal with Yumanity TherapeuticsJune 7, 2022 | msn.comShort Volatility Alert: Yumanity Therapeutics, Inc.June 6, 2022 | marketwatch.comYumanity to Sell Neurosciences Candidates, Merge With Kineta >YMTXJune 6, 2022 | seekingalpha.comYumanity stock soars 46% on all-stock merger with Kineta; lead product sale to J&J for $26MJune 6, 2022 | nasdaq.comYumanity Therapeutics To Sell 2 Product Candidates For $26 Mln In Cash; Inks Merger Deal With KinetaJune 6, 2022 | finance.yahoo.comYumanity Therapeutics Shares Trading Higher Today - Read Here WhyJune 6, 2022 | investorplace.comWhy Is Yumanity Therapeutics (YMTX) Stock Up 50% Today?June 6, 2022 | finance.yahoo.comYumanity Therapeutics Announces Definitive Agreements for Two Strategic TransactionsSee More Headlines Receive YMTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Yumanity Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/12/2021Today4/24/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:YMTX CUSIPN/A CIK1445283 Webwww.yumanity.com Phone(617) 409-5300FaxN/AEmployees40Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($3.00) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-39,500,000.00 Net Margins-660.61% Pretax Margin-660.61% Return on Equity-263.34% Return on Assets-107.08% Debt Debt-to-Equity RatioN/A Current Ratio2.21 Quick Ratio2.21 Sales & Book Value Annual Sales$4.84 million Price / Sales1.42 Cash FlowN/A Price / Cash FlowN/A Book Value$2.28 per share Price / Book0.28Miscellaneous Outstanding Shares10,856,000Free Float9,504,000Market Cap$6.89 million OptionableNot Optionable Beta0.32 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesDr. Richard Peters M.D. (Age 59)Ph.D., CEO, Pres & Director Comp: $896.1kDr. Vikram Khurana M.D.Ph.D., Scientific Co-Founder & Sr. Advisor of Discovery BiologyMs. Chee Yeun Chung Ph.D.Scientific Co-Founder & Associate Director of Discovery BiologyMs. Marie Epstein CPAVP of Fin.Mr. Michael D. Wyzga (Age 33)SVP, CFO & Treasurer Mr. Devin Whittemore Smith (Age 54)SVP, Gen. Counsel & Sec. More ExecutivesKey CompetitorsAdial PharmaceuticalsNASDAQ:ADILCadrenal TherapeuticsNASDAQ:CVKDProtagenic TherapeuticsNASDAQ:PTIXTenax TherapeuticsNASDAQ:TENXClever LeavesNASDAQ:CLVRView All Competitors YMTX Stock Analysis - Frequently Asked Questions How have YMTX shares performed in 2024? Yumanity Therapeutics' stock was trading at $3.63 at the beginning of the year. Since then, YMTX shares have decreased by 82.9% and is now trading at $0.62. View the best growth stocks for 2024 here. How were Yumanity Therapeutics' earnings last quarter? Yumanity Therapeutics, Inc. (NASDAQ:YMTX) released its quarterly earnings data on Thursday, August, 12th. The company reported ($1.03) EPS for the quarter, missing analysts' consensus estimates of ($0.84) by $0.19. The firm earned $2.11 million during the quarter, compared to analyst estimates of $2.27 million. Yumanity Therapeutics had a negative trailing twelve-month return on equity of 263.34% and a negative net margin of 660.61%. How do I buy shares of Yumanity Therapeutics? Shares of YMTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:YMTX) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsThe #1 Crypto for 2024InvestorPlaceDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingExposed: 10 CENT Crypto to Explode April 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Yumanity Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
